[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641819":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":11,"responsibleParty":31,"collaborators":11,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":11,"enrollmentInfo":43,"targetDuration":11,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":57,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":11},{"fullName":5,"class":6},"Centre Hospitalier de la côte Basque","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Connected home blood pressure monitoring with daily IPA supervision","EXPERIMENTAL",null,[13],"Device: Connected home blood pressure monitoring with daily IPA supervision.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","Connected home blood pressure monitoring with daily IPA supervision.","Use of a validated connected blood pressure monitor with Bluetooth gateway; standardized patient training; daily monitoring of transmitted BP measurements; scheduled clinical visits and telephone follow-up by the IPA.",[9],[21],{"name":22,"affiliation":23,"role":24},"Vanessa BEAU","Centre Hospitalier Côte Basque","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Séverine LABARRERE","CONTACT","+33559443828","slabarrere@ch-cotebasque.fr",{"type":24,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Mme BEAU Vanessa","Study nurse","100641819","connected-blood-pressure-monitoring-in-patients-with-hematologic-malignancies-initiating-covalent-btk-inhibitors-100641819",false,"NCT07592481","Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors","HEMO-CONNECT","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of lymphoid malignancy: chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma\n* Initiation of oral BTK inhibitor therapy (ibrutinib, acalabrutinib, or zanubrutinib), in treatment-naive or relapsed patients\n* Affiliation with a social security system\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Known cognitive impairment\n* No internet access\n* Individuals under guardianship, curatorship, or legal protection","ALL","18 Years",{"count":44,"type":45},40,"ESTIMATED","INTERVENTIONAL",[48],"NA","This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.",[51,52,53,54,55,56],"Chronic Lymphocytic Leukemia (CLL)","Follicular Lymphoma ( FL)","Waldenstrom Macroglobulinaemia","Lymphoplasmacytic Lymphoma","Marginal Zone B Cell Lymphoma","Mantle Cell Lymphoma",[58,59,60,61,62,63,64,65],"BTK inhibitor","Hypertension","Telemonitoring","Connected device","Blood pressure","Lymphoid malignancies","Advanced practice nursing","Cardio-oncology","NOT_YET_RECRUITING","2026-06-18",{"date":69,"type":70},"2026-06-22","ACTUAL",{"date":72,"type":45},"2026-07-01",{"date":74,"type":45},"2027-12-31",{"name":5,"class":6}]